The Recall Desk
ModerateFDA (Drugs)·D-0100-2020·Announced 2019-10-09

Sermorelin and GHRP-2 Lyophilized Vials Recalled Due to Sterility Concerns

KRS Global Biotechnology is recalling 120 vials of Sermorelin and GHRP-2 because the company cannot assure the products are sterile.

What this means for you

Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.

Our severity reasoning: The recall is classified as FDA Class II and involves a lack of assurance of sterility without reported injuries, fitting the criteria for moderate risk.

Plain-English summary

KRS Global Biotechnology, Inc. is recalling 120 vials of Sermorelin (3 mg) and GHRP-2 (3 mg) lyophilized powder for subcutaneous use. The recall affects all lots that remain within their expiration dates.

The recall was initiated because the manufacturer cannot provide assurance of the sterility of the product. This means there is a risk that the medication may be contaminated.

The affected product was distributed nationwide. Consumers or healthcare providers with the affected medication should contact the manufacturer for further instructions.

The recalled product

Product
Sermorelin, 3 mg / GHRP-2, 3 mg / Vial, For SC Use-Lyophilized, Rx Only, KRS Global Biotechnology 791 Park of Commerce Blvd, Boca Raton, FL 33487. NDC 3321674092
Affected units
120

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (1)

  • All lots remaining within expiry.

Distribution

Distributed nationwide across the United States.

Part of a larger recall action

This product is one of 80 recalled by KRS Global Biotechnology, Inc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.

See all 80 products in this recall →